Myasthenia gravis epidemiology in a national cohort; combining multiple disease registries

Acta Neurologica Scandinavica

Volumn 129, Issue S198, 2014, Pages 26-31

  Andersen, J B ^a   Heldal, A T ^a   Engeland, A ^a,b   Gilhus, N E ^a,c  

^a UNIVERSITY OF BERGEN   (Norway)

^b NORWEGIAN INSTITUTE OF PUBLIC HEALTH   (Norway)

^c HAUKELAND UNIVERSITY HOSPITAL   (Norway)

Author keywords

Acetylcholine receptor antibody test; Incidence; Myasthenia gravis; Prevalence; Pyridostigmine

Indexed keywords

CHOLINERGIC RECEPTOR ANTIBODY; PYRIDOSTIGMINE; AUTOANTIBODY;

ADULT; ARTICLE; CASE FINDING; COHORT ANALYSIS; DRUG INFORMATION; FEMALE; HUMAN; INCIDENCE; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; MYASTHENIA GRAVIS; NORWAY; ONSET AGE; PALLIATIVE THERAPY; PATIENT INFORMATION; PHARMACY; PRESCRIPTION; PREVALENCE; AGED; BLOOD; COMPLICATION; EPIDEMIOLOGY; IMMUNOLOGY; REGISTER; VERY ELDERLY; YOUNG ADULT;

ADULT; AGED; AGED, 80 AND OVER; AUTOANTIBODIES; COHORT STUDIES; FEMALE; HUMANS; INCIDENCE; MALE; MIDDLE AGED; MYASTHENIA GRAVIS; NORWAY; PREVALENCE; REGISTRIES; YOUNG ADULT;

EID: 84895484652     PISSN: 00016314     EISSN: 16000404     Source Type: Journal    
DOI: 10.1111/ane.12233     Document Type: Article

References (35)

1. Gilhus NE. Myasthenia and the neuromuscular junction. Curr Opin Neurol 2012;25:523-9.
2. Meriggioli MN, Sanders DB. Muscle autoantibodies in myasthenia gravis: beyond diagnosis? Expert Rev Clin Immunol 2012;8:427-38.
3. Vincent A, Wood H. Antibody specificity in myasthenia gravis. Monogr Allergy 1988;25:33-40.
4. Romi F, Gilhus NE, Aarli JA. Myasthenia gravis: disease severity and prognosis. Acta Neurol Scand Suppl 2006;183:24-5.
5. Evoli A. Clinical aspects of neuromuscular transmission disorders. Acta Neurol Scand Suppl 2006;183:8-11.
6. Zisimopoulou P, Brenner T, Trakas N, Tzartos SJ. Serological diagnostics in myasthenia gravis based on novel assays and recently identified antigens. Autoimmun Rev 2013;12:924-30.
7. Leite MI, Waters P, Vincent A. Diagnostic use of autoantibodies in myasthenia gravis. Autoimmunity 2010;43:371-9.
8. Gomez AM, Van Den Broeck J, Vrolix K et al. Antibody effector mechanisms in myasthenia gravis-pathogenesis at the neuromuscular junction. Autoimmunity 2010;43:353-70.
9. Carr AS, Cardwell CR, McCarron PO, McConville J. A systematic review of population based epidemiological studies in Myasthenia Gravis. BMC Neurol 2010;10:46.
10. McGrogan A, Sneddon S, de Vries CS. The incidence of myasthenia gravis: a systematic literature review. Neuroepidemiology 2010;34:171-83.
11. Furu K. Establishment of the nationwide Norwegian Prescription Database (NorPD) - new opportunities for research in pharmacoepidemiology in Norway. Nor J Epidemiol 2008;18:129-36.
12. Furu K, Wettermark B, Andersen M, Martikainen JE, Almarsdottir AB, Sorensen HT. The Nordic countries as a cohort for pharmacoepidemiological research. Basic Clin Pharmacol Toxicol 2010;106:86-94.
13. The Research Council of Norway. Evaluation of biology, medicine and health research in Norway. Oslo 2011.
14. Heldal AT, Owe JF, Gilhus NE, Romi F. Seropositive myasthenia gravis: a nationwide epidemiologic study. Neurology 2009;73:150-1.
15. Heldal AT, Eide GE, Gilhus NE, Romi F. Geographical distribution of a seropositive myasthenia gravis population. Muscle Nerve 2012;45:815-9.
16. Andersen JB, Engeland A, Owe JF, Gilhus NE. Myasthenia gravis requiring pyridostigmine treatment in a national population cohort. Eur J Neurol 2010;17:1445-50.
17. Spillane J, Higham E, Kullmann DM. Myasthenia gravis. BMJ 2012;345:e8497.
18. Skeie GO, Apostolski S, Evoli A et al. Guidelines for the treatment of autoimmune neuromuscular transmission disorders. Eur J Neurol 2006;13:691-9.
19. Jacob S, Viegas S, Lashley D, Hilton-Jones D. Myasthenia gravis and other neuromuscular junction disorders. Pract Neurol 2009;9:364-71.
20. Gattellari M, Goumas C, Worthington JM. A national epidemiological study of Myasthenia Gravis in Australia. Eur J Neurol 2012;19:1413-20.
21. Pedersen EG, Hallas J, Hansen K, Jensen PE, Gaist D. Identifying patients with myasthenia for epidemiological research by linkage of automated registers. Neuroepidemiology 2011;37:120-8.
22. Somnier FE. Anti-acetylcholine receptor (AChR) antibodies measurement in myasthenia gravis: the use of cell line TE671 as a source of AChR antigen. J Neuroimmunol 1994;51:63-8.
23. Lefvert AK, Bergstrom K, Matell G, Osterman PO, Pirskanen R. Determination of acetylcholine receptor antibody in myasthenia gravis: clinical usefulness and pathogenetic implications. J Neurol Neurosurg Psychiatry 1978;41:394-403.
24. Romi F, Gilhus NE, Varhaug JE, Myking A, Aarli JA. Disease severity and outcome in thymoma myasthenia gravis: a long-term observation study. Eur J Neurol 2003;10:701-6.
25. Vincent A, Leite MI, Farrugia ME et al. Myasthenia gravis seronegative for acetylcholine receptor antibodies. Ann N Y Acad Sci 2008;1132:84-92.
26. Ferrero B, Aimo G, Pagni R et al. Modified and improved anti-acetylcholine receptor (AchR) antibody assay: comparison of analytical and clinical performance with conventional anti-AChR antibody assay. Clin Chem 1997;43:824-31.
27. Lai CH, Tseng HF. Nationwide population-based epidemiological study of myasthenia gravis in taiwan. Neuroepidemiology 2010;35:66-71.
28. Meyer A, Levy Y. Geoepidemiology of myasthenia gravis [corrected]. Autoimmun Rev 2010;9:A383-6.
29. Gilhus NE. Autoimmune myasthenia gravis. Expert Rev Neurother 2009;9:351-8.
30. Mantegazza R, Baggi F, Antozzi C et al. Myasthenia gravis (MG): epidemiological data and prognostic factors. Ann N Y Acad Sci 2003;998:413-23.
31. Aarli JA. Myasthenia gravis in the elderly: is it different? Ann N Y Acad Sci 2008;1132:238-43.
32. Mao ZF, Mo XA, Qin C, Lai YR, Olde Hartman TC. Course and prognosis of myasthenia gravis: a systematic review. Eur J Neurol 2010;17:913-21.
33. Somnier FE, Keiding N, Paulson OB. Epidemiology of myasthenia gravis in Denmark. A longitudinal and comprehensive population survey. Arch Neurol 1991;48:733-9.
34. Giagheddu M, Puggioni G, Sanna G et al. Epidemiological study of myasthenia gravis in Sardinia, Italy (1958-1986). Acta Neurol Scand 1989;79:326-33.
35. Hoff JM, Daltveit AK, Gilhus NE. Myasthenia gravis in pregnancy and birth: identifying risk factors, optimising care. Eur J Neurol 2007;14:38-43.